Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease

scientific article published on 04 September 2019

Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41409-019-0662-6
P698PubMed publication ID31484991

P50authorKyle R BrownbackQ88488742
Christopher StreilerQ93106881
P2093author name stringSunil Abhyankar
Christian Davis
Faizan Shaikh
P2860cites workNational Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group reportQ35085226
Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell TransplantationQ36712018
Diagnosis and manifestations of chronic graft-versus-host diseaseQ37173472
Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical TrialQ38372551
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantationQ43579107
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host diseaseQ49724160
Activity of therapeutic JAK 1/2 blockade in graft-versus-host diseaseQ87635679
Ruxolitinib is an effective steroid sparing agent in children with steroid refractory/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantationQ91229389
P921main subjectbronchiolitisQ424227
bronchiolitis obliteransQ614750
ruxolitinibQ7383611
P577publication date2019-09-04
P1433published inBone Marrow TransplantationQ4941523
P1476titleRuxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease

Search more.